Exact Sciences Corporation
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000CWL0F5
EXAS
Exact Sciences Corporation
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Diagnostics & Research
NAME
Exact Sciences Corporation
ISIN
US30063P1057
TICKER
EXAS
MIC
XNAS
REUTERS
EXAS.OQ
BLOOMBERG
EXAS US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 02.01.2025
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
J.P. Morgan Healthcare Conference, San Francisco
Presentation followed by Q&A on Monday, January 13, 2025 at 1...
Exact Sciences
Di., 26.11.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Citi Global Healthcare Conference, Miami
Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET
Evercore ...
Exact Sciences
Mo., 25.11.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas.
“Exact Sciences is committed to improving breast canc...
Exact Sciences
Mi., 13.11.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and...
Exact Sciences
Di., 05.11.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 million for the third quarter ended September 30, 2024, compared to $628 million for the same period of 2023.
“The Exact Sciences’ team is helping eradicate cancer while strengthening our pla...
Exact Sciences
Fr., 01.11.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jefferies London Healthcare Conference, London
Fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET
The we...
Exact Sciences
So., 27.10.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus™ test during the American College of Gastroenterology (ACG) Annual Meeting. ACG ta...
Exact Sciences
Di., 08.10.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. E...
Exact Sciences
Fr., 04.10.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved the Cologuard Plus™ test, the company’s next generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colo...
Exact Sciences
Mo., 16.09.2024
Exact Sciences
US30063P1057
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy....
Exact Sciences
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
